Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
March 20, 2020
Mortality and Complication Rates in Adult Trauma Patients Receiving Tranexamic Acid: A Single-center Experience in the Post-CRASH-2 Era
Pablo Joaquin Erramouspe, María Florencia García-Pintos, Simranjeet Benipal, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 28, 2007
Benzopyran sulfonamides as KV1.5 potassium channel blockers
John Lloyd, Karnail S Atwal, Heather J Finlay, et al.
The New Phytologist
|
March 24, 2020
Geographic variation in the genetic basis of resistance to leaf rust between locally adapted ecotypes of the biofuel crop switchgrass (Panicum virgatum)
Acer VanWallendael, Jason Bonnette, Thomas E Juenger, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 8, 2013
2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents
Zulan Pi, James Sutton, John Lloyd, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 19, 2013
Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists
Heather J Finlay, Ji Jiang, Yolanda Caringal, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 3, 2014
Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors
James A Johnson, Ningning Xu, Yoon Jeon, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 26, 2010
Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers
John Lloyd, Heather J Finlay, Wayne Vacarro, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 12, 2009
Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists
John Lloyd, Heather J Finlay, Karnail Atwal, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 25, 2015
Pseudosaccharin amines as potent and selective KV1.5 blockers
John Lloyd, Heather J Finlay, Alexander Kover, et al.
Expert Opinion on Biological Therapy
|
February 19, 2020
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Matthew Chiu, Edward John Lloyd Armstrong, Vicki Jennings, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
March 20, 2020
Mortality and Complication Rates in Adult Trauma Patients Receiving Tranexamic Acid: A Single-center Experience in the Post-CRASH-2 Era
Pablo Joaquin Erramouspe, María Florencia García-Pintos, Simranjeet Benipal, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 28, 2007
Benzopyran sulfonamides as KV1.5 potassium channel blockers
John Lloyd, Karnail S Atwal, Heather J Finlay, et al.
The New Phytologist
|
March 24, 2020
Geographic variation in the genetic basis of resistance to leaf rust between locally adapted ecotypes of the biofuel crop switchgrass (Panicum virgatum)
Acer VanWallendael, Jason Bonnette, Thomas E Juenger, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 8, 2013
2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents
Zulan Pi, James Sutton, John Lloyd, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 19, 2013
Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists
Heather J Finlay, Ji Jiang, Yolanda Caringal, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 3, 2014
Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors
James A Johnson, Ningning Xu, Yoon Jeon, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 26, 2010
Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers
John Lloyd, Heather J Finlay, Wayne Vacarro, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 12, 2009
Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists
John Lloyd, Heather J Finlay, Karnail Atwal, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 25, 2015
Pseudosaccharin amines as potent and selective KV1.5 blockers
John Lloyd, Heather J Finlay, Alexander Kover, et al.
Expert Opinion on Biological Therapy
|
February 19, 2020
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Matthew Chiu, Edward John Lloyd Armstrong, Vicki Jennings, et al.
Page
of 9